Multiple Sclerosis cases are rising in India, especially among women, with experts stressing early diagnosis, access to ...

Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Ocrevus appears to be a safe and effective treatment for children and adolescents with MS, according to real-world data from ...

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing ...

Early diagnosis and treatment aim to minimise the impact of multiple sclerosis on their daily lives and extend their ...

RRMS is the most common type of multiple sclerosis ... including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

MS is a spectrum of diseases, //sometimes mimicking tumors (TMS) The Unseen Struggle That Demands Global Solidarity World ...